Michael R. Bishop to Lymphoma
This is a "connection" page, showing publications Michael R. Bishop has written about Lymphoma.
Connection Strength
1.787
-
Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. Bone Marrow Transplant. 2018 01; 53(1):11-21.
Score: 0.543
-
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol. 2012 Mar 10; 30(8):830-6.
Score: 0.367
-
Allogeneic hematopoietic stem cell transplantation for lymphoma. Clin Lymphoma. 2004 Mar; 4(4):238-49.
Score: 0.212
-
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant. 2003 Mar; 9(3):162-9.
Score: 0.197
-
Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant. 1998 Jan; 21(1):33-41.
Score: 0.138
-
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365.
Score: 0.137
-
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46.
Score: 0.082
-
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells. Leuk Lymphoma. 2001 Jul; 42(3):417-27.
Score: 0.044
-
Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Bone Marrow Transplant. 1996 Jun; 17(6):951-6.
Score: 0.031
-
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant. 2011 Nov; 17(11):1619-29.
Score: 0.022
-
Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol. 2005 Apr; 78(4):265-74.
Score: 0.014